acridines and su 11248
acridines has been researched along with su 11248 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Beijnen, JH; Hillebrand, MJ; Lagas, JS; Lankheet, NA; Poller, B; Rosing, H; Schinkel, AH; Tang, SC | 1 |
| Beijnen, JH; Lankheet, NA; Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E | 1 |
| Arano, Y; Gushimiyagi, K; Kashiba, T; Nomura, Y; Sato, H; Sekine, Y; Siddig, S; Suzuki, S; Uehara, T; Ueno, K; Uzu, M; Yamaura, K | 1 |
Other Studies
3 other study(ies) available for acridines and su 11248
| Article | Year |
|---|---|
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Topics: Acridines; Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Dogs; Drug Resistance, Multiple; Humans; Indoles; Male; Mice; Mice, Knockout; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Tissue Distribution | 2012 |
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Brain; Cell Line; Dogs; Humans; Indoles; Male; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Pyrroles; Sunitinib; Tetrahydroisoquinolines | 2012 |
Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Kinetics; Membrane Transport Modulators; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Sunitinib; Tetrahydroisoquinolines | 2015 |